Results 31 to 40 of about 2,050 (152)

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Emergence of plasmid-borne tet(X4) resistance gene in clinical isolate of eravacycline- and omadacycline-resistant Klebsiella pneumoniae ST485

Microbiology Spectrum
Omadacycline and eravacycline are gradually being used as new tetracycline antibiotics for the clinical treatment of Gram-negative pathogens. Affected by various tetracycline-inactivating enzymes, there have been reports of resistance to eravacycline and
Xiaojing Liu, Yi Liu, Xiaohan Ma, Ruyan Chen, Chenyu Li, Hongxin Fu, Yu Yang, Kexin Guo, Xiaoping Zhang, Ruishan Liu, Hao Xu, Junfei Zhu, Beiwen Zheng   +12 more
doaj   +2 more sources

Early Clinical Response of a Large Amebic Liver Abscess to Eravacycline Prior to Metronidazole Initiation: A Case Report. [PDF]

Case Rep Infect Dis
Entamoeba histolytica is an amebic protozoan that is often asymptomatic, with many patients being asymptomatic carriers. However, 10 percent of cases manifest with amebic dysentery and, less commonly, amebic liver abscesses. Amebic liver abscesses are the most common extraintestinal manifestation of E. histolytica.
Anthony JA, Robinson A, Pedroza L.
europepmc   +2 more sources

The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis

Frontiers in Medicine, 2022
BackgroundEravacycline is a novel, fully synthetic fluorocycline antibiotic for the treatment of adults with complicated intra-abdominal infections (cIAIs).
Rui Meng, Rui Meng, Xin Guan, Xin Guan, Lei Sun, Lei Sun, Zhengyang Fei, Zhengyang Fei, Yuxin Li, Yuxin Li, Mengjie Luo, Mengjie Luo, Aixia Ma, Aixia Ma, Hongchao Li, Hongchao Li   +15 more
doaj   +1 more source

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Frontiers in Microbiology, 2022
In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus
Weiliang Zeng, Xiaotuan Zhang, Yan Liu, Yi Zhang, Mengxin Xu, Sipei Wang, Yao Sun, Tieli Zhou, Lijiang Chen   +8 more
doaj   +1 more source

Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae

Emerging Microbes and Infections, 2018
This study investigated the characteristics and mechanisms of eravacycline resistance and heteroresistance in clinical Klebsiella pneumoniae isolates. A total of 393 clinical K.
Jin-xin Zheng, Zhi-wei Lin, Xiang Sun, Wei-hong Lin, Zhong Chen, Yang Wu, Guo-bin Qi, Qi-wen Deng, Di Qu, Zhi-jian Yu   +9 more
doaj   +1 more source

AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis

Frontiers in Microbiology, 2020
Carbapenem-resistant Acinetobacter nosocomialis (CRAn) is a significant public health concern. Tigecycline non-susceptible CRAn (Tn-CRAn) isolates have emerged worldwide.
Yi-Tzu Lee, Yi-Tzu Lee, Hsing-Yu Chen, Ya-Sung Yang, Yu-Ching Chou, Tein-Yao Chang, Wei-Jane Hsu, I-Chieh Lin, ACTION Study Group, Jun-Ren Sun   +9 more
doaj   +1 more source

In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: a Multicenter Study in China, 2019

Microbiology Spectrum, 2023
Aztreonam-avibactam, eravacycline, and cefoselis are three novel antimicrobial agents for the treatment of serious infections caused by Gram-negative bacteria. We evaluated the in vitro activities of the above-mentioned three antimicrobial agents against
Jiawei Chen, Yong Liu, Wei Jia, Xuesong Xu, Guizhen Sun, Tong Wang, Jin Li, Ge Zhang, Ran Jing, Hongli Sun, Yingchun Xu, Yali Liu   +11 more
doaj   +1 more source

In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates

, 2021
The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains.
Ataman, Merve, Mataraci-Kara, Emel, Ozbek-Celik, Berna   +2 more
core   +1 more source

Standard curves of tetracycline, rifamycin SV, and eravacycline.

, 2021
(A) The standard curve of tetracycline was generated using the reporter strain E. coli ΔtolC treated with E. coli HM22 lysates supplemented with known concentrations of tetracycline. (B) The standard curve of rifamycin SV was generated using the reporter
Karin Sauer (1993), Huan Gu (1918261), Shikha Nangia (1322931), Dacheng Ren (133429), Sweta Roy (11824859), Ali Adem Bahar (11824862)   +5 more
core   +1 more source